<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901183</url>
  </required_header>
  <id_info>
    <org_study_id>CardioVeg</org_study_id>
    <nct_id>NCT03901183</nct_id>
  </id_info>
  <brief_title>Plant-based Nutrition for Patients With Cardiovascular Risk Factors</brief_title>
  <acronym>CardioVeg</acronym>
  <official_title>Plant-based Nutrition for Patients With Cardiovascular Risk Factors - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Department for Dental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plant-based nutrition may have positive effects on chronic diseases such as cardiovascular or
      metabolic disorders. This study investigates the effects of a 8 week plant-based diet for
      patients with metabolic syndrom and cardiovascular risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of baseline Composite Score for Metabolic Syndrom (Standardizing Physiological Composite Risk Endpoints (SCORE)) at 2 months</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks</time_frame>
    <description>Composite score including waist wircumference, blood pressure, fasting blood glucose, tryglycerids, HDL-cholesterin Range 0-100, lower score meaning a better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bio-electrical Impedance Analysis (BIA)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Estimation of the body composition via bio-electrical impedance analysis (body fat and visceral fat in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bio-electrical Impedance analysis (BIA)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Estimation of the body composition via bio-electrical impedance analysis (muscle mass in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline systolic blood pressure at 2 months</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Average of 24h measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline diastolic blood pressure at 2 months</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Average of 24h measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose (mmol/l)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Triglycerides (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin (µU/ml)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1c) (%)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamin (µmol/l)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic model assessment (HOMA-IR)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Index calculated from Insulin (µU/ml) x fasting glucose (mmol/l) / 22,5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin (µg/l)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Hepatic transaminases (GPT, GOT in U/L) and Gamma glutamyl transpeptidase (y-GT in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Folic acid (ng/ml)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid (mg/dl)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holotranscobalamin (pmol/L)</measure>
    <time_frame>Date of inclusion (baseline), after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trimethylamine N-oxide (mg/dl)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire (WHO-5)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Change from Baseline in the WHO-5, range from 0 to 100 % while higher values meaning a higher grade of well-being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress questionnaire (Cohen Perceived Stress Scale, CPSS)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Change from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 &amp; 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Self-efficacy Short Scale (ASKU)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 3-15, higher score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 0-42, lower score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study Short Form (MOS SF-12)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 0-100, higher score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zerssen symptom list (B-LR and B-LR')</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 20-80, higher score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intuitive Eating Scale 2 (IES-2)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 23-115, higher score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flourishing Scale (FS-D)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Assessing full scale, range 8-56, higher score meaning a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire (IPAQ )</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>MET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (kg/m2)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (cm)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wrist Circumference (cm)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Measuring systolic and diastolic blood pressure in 20-minute-intervals for 24h with &quot;Spacelabs&quot; devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Behaviour</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Nutritional history via dietary weight record (each for 3 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily nutrition protocol</measure>
    <time_frame>Daily throughout the entire survey period</time_frame>
    <description>Via the App 'Calorie Counter - Fddb Extender'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication intake</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Name of medication and dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio Vascular Risc Profile</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Cardio Vascular Risc in % with following scores: SCORE-Deutschland/PROCAM/arriba/WHO-ISH Charts/BEWAT-Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>16S rRNA Sequencing / Shotgun Sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Oxygenization</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion (upper arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Temperature</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion and Empatica E4 devices (upper arm/wrist)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Faros 180 (chest), Biovotion Everion and Empatica E4 (upper arm/wrist) devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Faros 180 (chest), Biovotion Everion and Empatica E4 (upper arm/wrist) devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interbeat Interval (IBI)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion and Empatica E4 devices (upper arm/wrist)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiration Rate</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Volume Pulse</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Empatica E4 device (wrist)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrodermal Activity (Galvanic Skin Response)</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion device and Empatica E4 (upper arm/wrist) devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Steps per 24 hours</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>24h measuring by Biovotion Everion device (upper arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sociodemographic Measurements</measure>
    <time_frame>Date of inclusion (baseline)</time_frame>
    <description>Age, gender, education level, household income, employment status, marital status, language spoken, complete family history, current and previous illness and co-morbidities, and current medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Health Qualitative Interviews</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>using the German version of the &quot;Oral Health Impact Profile&quot; with 21 questions, score ranges from 0 to 21, high score Shows a low Quality of oral health, low score Shows a high Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of inflammatory oral conditions</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>bleeding index (gingival bleeding index, bleeding on probing) in percentage, ranges from 0 to 100 %, optimal is less then 15 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of teeth related conditions</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>dental findings (attrition, bruxism, caries, dental implants, dentures, missing teeth, erosions, restorations (all classes))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Oral Fluids</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>crevicular fluid rate, salivary flow (stimulated, unstimulated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of periodontal attachment level</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>probing pocket depth, recessions, measuring in mm on 6 sites per tooth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of oral hygiene</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>Plaque Index in %, ranges from 0 to 100%, less then 15 % Shows an optimal oral hygiene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of periodontal status</measure>
    <time_frame>Date of inclusion (baseline), after 8 weeks, after 16 weeks</time_frame>
    <description>measuring with periodontal Screening index, ranges from 0 to 4, code 0 - oral health, 1-2 Gingivitis, 3-4 Periodontitis, additional findings as furcation involvement and loosening are documented</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Qualitative interviews in focus groups interviews</measure>
    <time_frame>16 weeks after inclusion</time_frame>
    <description>Qualitative assessment will be carried out in 45-minute focus group interviews in 12 (randomized selected) patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Hypertension,Essential</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plant-based Diet</intervention_name>
    <description>Patients are guided to change their nutrition to a plant-based diet.</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood pressure &gt; 140 mmHg systolic and/or &gt; 90 mmHg diastolic, in case of medication
             also increased values &gt; 140 mmHg systolic and/or &gt; 90 mmHg diastolic needed

          -  Adipositas with a waist circumference of &gt; 94 cm in men and &gt; 80 cm in women

          -  A non-vegetarian diet in the past 6 months (at least 4x meat and/or meat products per
             week, at least 5x dairy products per week)

          -  No fasting, no specific diet or change of diet in the last 2 months

          -  Weight stable over the last two months (+- 3 kg)

          -  Medication unchanged for at least one month

          -  No fasting, no change of diet in the last 2 months

        Exclusion Criteria:

          -  Poor general condition

          -  Coronary heart disease

          -  Diabetes mellitus Type I

          -  Cerebrovascular diseases

          -  Severe mental illness

          -  Severe acute or chronic comorbidity

          -  Pregnancy and lactation or planned pregnancy in the next 6 months

          -  Eating disorder

          -  Max. 2 beers 0,5l or 2 wines 0,2l per day

          -  No alcohol abstinence 48 hours before blood samples possible

          -  Max. 5 cigarettes/day

          -  Medicine that affect weight

          -  Antibiotics within the last 6 months

          -  Major surgery &lt;6 months prior to randomization

          -  BMI &gt; 40 kg/m2

          -  Existing vegetarian or plant-based diet

          -  Bariatric surgery (obesity surgery)

          -  Simultaneous participation in another clinical trial

          -  Participation in a clinical trial within the last 3 months prior to inclusion in the
             study

          -  Lack of consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite - Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Roesner</last_name>
    <phone>+49 30 80505 682</phone>
    <email>m.roesner@immanuel.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Roesner</last_name>
      <phone>030 80505 682</phone>
      <email>m.roesner@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Michalsen, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Michalsen</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Metabolic Syndrom</keyword>
  <keyword>Plant-based Diet</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

